CVS Settles $50M Insulin Fraud Case

CVS faces a $50 million settlement over allegedly fraudulent insulin pen billing to Medi-Cal, spanning a decade from 2010 to 2020. The pharmacy allegedly overcharged by dispensing more insulin than prescribed and refilling prescriptions prematurely, tricking the system into approving unnecessary payments. California’s Attorney General hailed the resolution as a victory for accountability, ensuring public funds serve those who truly need them. The case, aided by whistleblowers and joint state-federal efforts, remains based on allegations—no guilt has been proven—but the settlement underscores the critical role of transparency and speaking up when public resources are at risk. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e844261a11587b0b